Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000069

Drug Information
NameBimosiamose
SynonymsTBC-1269; Bimosiamose; CHEBI:787792; 187269-40-5; UNII-97B5KCW80W; CID 9811353; (1,1'-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-(alpha-D-mannopyranosyloxy)-; CID9811353; TBC 1269; CHEMBL1215923
CompanyEncysive Pharma.
IndicationAsthma
[ICD9: 493   ICD10: J45]
Phase II    [1]
Chronic Obstructive Pulmonary DiseasePhase IIa    [1]
Inflammatory DisordersPhase II    [1]
Psoriasis and Psoriatic Disorders, Atopic Dermatitis
[ICD9: 691.8, 692.9, 696   ICD10: L20, L20-L30, L40]
Phase IIa completed    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C46H54O16/c47-23-35-39(53)41(55)43(57)45(61-35)59-33-15-13-25(
19-31(33)29-11-5-9-27(17-29)21-37(49)50)7-3-1-2-4-8-26-14-16-34(6
0-46-44(58)42(56)40(54)36(24-48)62-46)32(20-26)30-12-6-10-28(18-3
0)22-38(51)52/h5-6,9-20,35-36,39-48,53-58H,1-4,7-8,21-24H2,(H,49,
50)(H,51,52)/t35-,36-,39-,40-,41+,42+,43+,44+,45+,46+/m1/s1
InChIKeyRYWCQJDEHXJHRI-XJMXIVSISA-N
Canonical SMILESC1=CC(=CC(=C1)CC(=O)O)C2=C(C=CC(=C2)CCCCCCC3=CC(=C(C=C3)OC4C(C(C(C(O4)
CO)O)O)O)C5=CC(=CC=C5)CC(=O)O)OC6C(C(C(C(O6)CO)O)O)O    
Isomeric SMILESC1=CC(=CC(=C1)CC(=O)O)C2=C(C=CC(=C2)CCCCCCC3=CC(=C(C=C3)O[C@@H]4[C@H](
[C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=CC(=CC=C5)CC(=O)O)O[C@@H]6[C@H]([C@H](
[C@@H]([C@H](O6)CO)O)O)O
CAS NumberCAS 187269-40-5
PubChem Compound IDCID 9811353.
PubChem Substance IDSID 10549630.
ClinicalTrials.govNCT00823693;
NCT00962481;
TargetSelectinInhibitor[2][3][4]
Ref 1Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. To Reference
Ref 2Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82. To Reference
Ref 3The pharmacokinetics of subcutaneously injected Bimosiamose disodium in healthy male volunteers. Biopharm Drug Dispos. 2007 Dec;28(9):475-84. To Reference
Ref 4Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther. 2006;19(4):233-41. Epub 2005 Sep 1. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543